MedTrace Logo

Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness

NCT00745771 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2009-03-20

No results posted yet for this study

Summary

Multiple-dose, double-blind, double-dummy, parallel, randomized, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for muscle soreness from exercise.

Conditions

  • Muscle Soreness

Interventions

DRUG

Diractin

DRUG

Diractin

Sponsors & Collaborators

  • IDEA AG

    lead INDUSTRY

Principal Investigators

  • Egbert Seidel, MD · X-pert Med Jena

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-02-29
Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745771 on ClinicalTrials.gov